Market Place
Sourcing Support
Ikena Oncology and Inmagene Announce Merger, Placement
23 Dec 2024 //
GLOBENEWSWIRE
Ikena Oncology Reports Q3 2024 Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
Ikena Oncology Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Ikena Onco weighs ‘strategic options’ as it drops cancer asset, trims headcount
29 May 2024 //
ENDPTS
UPDATE “ Ikena Oncology Announces Strategic Update
28 May 2024 //
GLOBENEWSWIRE
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10 Apr 2024 //
GLOBENEWSWIRE
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
27 Feb 2024 //
GLOBENEWSWIRE
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
21 Feb 2024 //
GLOBENEWSWIRE
Jilted by BMS, Ikena cuts headcount by 35% in discovery retreat
19 Jan 2024 //
FIERCE BIOTECH
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
18 Jan 2024 //
GLOBENEWSWIRE
Ikena Oncology Shares Initial Positive Escalation Data from IK-930
09 Nov 2023 //
GLOBENEWSWIRE
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Ikena Oncology to Participate in September 2023 Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Ikena Oncology Reports Second Quarter 2023 Financial Results & Corporate Update
10 Aug 2023 //
GLOBENEWSWIRE
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
07 Aug 2023 //
GLOBENEWSWIRE
Ikena Oncology to Participate in Upcoming Investor Conferences
24 May 2023 //
GLOBENEWSWIRE
Ikena Oncology Announces $40 Million Underwritten Offering
15 May 2023 //
GLOBENEWSWIRE
Ikena Oncology Reports 1Q 2023 FYR Results & Highlights Advancements Across
15 May 2023 //
GLOBENEWSWIRE
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
20 Apr 2023 //
GLOBENEWSWIRE
Ikena Oncology Shares Differentiation Profile of IK-930
17 Apr 2023 //
GLOBENEWSWIRE
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Ikena Oncology Presents Preclinical Data on IK-595
07 Mar 2023 //
GLOBENEWSWIRE
Ikena Receives FDA Fast Track Designation for IK-175 with Nivolumab
06 Mar 2023 //
GLOBENEWSWIRE
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Ikena Oncology Appoints Owen Hughes as Board Chair
19 Dec 2022 //
GLOBENEWSWIRE
Ikena Oncology drops an early-stage program as it looks to stretch its cash
29 Nov 2022 //
ENDPTS
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition
28 Nov 2022 //
GLOBENEWSWIRE
Ikena to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Ikena Oncology Announces Initial Clinical Data from IK-175 Program
10 Nov 2022 //
GLOBENEWSWIRE
Ikena Oncology Reports 3Q 2022 Financial Results and Provides a Corporate Update
07 Nov 2022 //
GLOBENEWSWIRE
Ikena Oncology Reports 3Q 2022 Financial Results and Provides a Corporate Update
07 Nov 2022 //
GLOBENEWSWIRE
Ikena Oncology Presents Data at EORTC-NCI-AACR Symposium on IK-930
26 Oct 2022 //
GLOBENEWSWIRE
Ikena Provides R&D Update on IK-930 Program Targeting the Hippo Pathway
18 Oct 2022 //
GLOBENEWSWIRE
Ikena Oncology to Present Initial Ph1a/b from Novel AHR Inhibition Program
05 Oct 2022 //
GLOBENEWSWIRE
Ikena Oncology to Participate in September 2022 Investor Conferences
06 Sep 2022 //
GLOBENEWSWIRE
Ikena Oncology Reports Q2 2022 Rusult and Provides a Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
06 Jul 2022 //
GLOBENEWSWIRE
Ikena Oncology Receives FDA FTD for Novel TEAD Inhibitor IK-930
22 Jun 2022 //
GLOBENEWSWIRE
Ikena Oncology to Participate in Spring 2022 Investor Conferences
18 May 2022 //
GLOBENEWSWIRE
Ikena Oncology Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Ikena Oncology to Present at the ASCO 2022 Annual Meeting
28 Apr 2022 //
GLOBENEWSWIRE
Ikena Appoints Jotin Marango as CFO and Head of Corporate Development
13 Apr 2022 //
GLOBENEWSWIRE
Ikena Oncology Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Ikena Oncology to Present PC Findings on IK-930 At AACR
07 Mar 2022 //
GLOBENEWSWIRE
Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors
26 Jan 2022 //
GLOBENEWSWIRE
Ikena Appoints Michelle Zhang as CSO
08 Dec 2021 //
GLOBENEWSWIRE
Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD
02 Nov 2021 //
BIOSPACE
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data
01 Oct 2021 //
GLOBENEWSWIRE
Ikena to Participate in Targeted Oncology Panel at William Blair Conference 2021
08 Jul 2021 //
GLOBENEWSWIRE
Ikena Oncology Announces Closing of Initial Public Offering and Exercise
30 Mar 2021 //
BUSINESSWIRE
Another 4 pharmas make the fabled Nasdaq leap, with combined raise rapidly $4.5B
27 Mar 2021 //
ENDPTS
Ikena bags $120M to advance growing pipeline of cancer drugs
05 Jan 2021 //
FIERCEBIOTECH
Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds
04 Jan 2021 //
BUSINESSWIRE
Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175
09 Nov 2020 //
BIOSPACE
Ikena Oncology Announces Publication Nature Communications of Preclinical Data
12 Aug 2020 //
NATURE
Ikena Oncology Announces Publication in Nature of Preclinical Data Supporting
11 Aug 2020 //
BUSINESSWIRE
Ikena Oncology Presents New Preclinical Data Anti-Cancer Effects of TEAD
22 Jun 2020 //
BUSINESSWIRE
